PCI Biotech Holding ASA
Oslo Stock Exchange PCIB.OL
PCI Biotech Holding ASA Market Capitalization on January 14, 2025: USD 4.06 M
-
PCI Biotech Holding ASA 52-week high Market Capitalization is USD 10.05 M on May 28, 2024, which is 147.34% above the current Market Capitalization.
-
PCI Biotech Holding ASA 52-week low Market Capitalization is USD 3.91 M on December 30, 2024, which is -3.78% below the current Market Capitalization.
-
PCI Biotech Holding ASA average Market Capitalization for the last 52 weeks is USD 6.06 M.
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
| CEO | Mr. Ronny Skuggedal |
| IPO Date | June 23, 2008 |
| Location | Norway |
| Headquarters | UllernchaussEen 64 |
| Employees | 6 |
| Sector | Health Care |
| Industries | |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email